ABSTRACT
Background Respiratory syntactical virus (RSV) is a common cause for severe lower respiratory tract infections (LRTI) in children <2 years of age in Germany – though little is known about the clinical and economic burden of RSV in children with and without risk factors per month of life.
Methods In a retrospective health claims analysis, we identified RSV inpatient cases between 2014 and 2019. We assessed incidence rates, mortality rate, health resource utilization, associated direct costs per case and excess costs for 30, 90 and 365 days after hospital admission matched to a control group. The outcomes are reported separately for the first and second year of life (i.e., for infants and toddlers) and were stratified by month of life, preterm and risk status (i.e., presence of underlying disease: chronic respiratory or cardiac disease, immunosuppression, neurological diseases, diabetes, conditions originating in the perinatal period).
Results RSV-attributable hospital incidence rate was higher in infants (30.25/1,000) than toddlers (14.52/1,000), highest in the first three months of life (44.21/1,000), in infants born preterm (64.76/1,000) or with any underlying disease (54.85/1,000). Mortality rate was also higher for infants (0.08/1,000) than toddlers (0.04/1,000). Mean 30-day excess costs ranged from 2,953 € for infants born full-term at no risk, hospitalized for 5 days, to 6,694 € for infants born extremely premature, hospitalized for 7 days.
Conclusion In Germany, the clinical and economic burden of RSV is substantial, especially in the most vulnerable population, that is, very young infants, those born premature and/or those with an underlying disease.
Competing Interest Statement
CL, LB, GB and CvE are all employees of Pfizer Pharma GmbH in Germany, the sponsor of this study. SM and JR are employees of Gesundheitsforen Leipzig GmbH, paid by Pfizer to conduct the study. BH is a former employee of Pfizer Pharma GmbH Germany. TT is an expert in the field of RSV and received an honorarium from Pfizer for input on the study design and review of the results.
Funding Statement
This study was funded by Pfizer Pharma GmbH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used aggregated and anonymized data, therefore not requiring approval from Institutional Review Boards or Ethical Committees or informed consents from patients.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
We have reanalysed the data. Due to a coding mistake, in the previous version, the study population only included RSV-specific cases but not not seasonal RSV-attributable UBP cases which we intended to also include. We now additionally stratify all outcomes by episode type (RSV-specific vs RSV-attributable UBP) to reveal the contribution of both types to the overall burden of RSV. We now report the number of cases identified in the database instead of extrapolated data. However, we do extrapolate costs to the popualtion level to describe the total economic burden for the German healthcare system. All tables and figures have been updated and revised.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
